Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

155.56 -0.36 (-0.23%)
Official Closing Price Updated: 7:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Resilient Investing: 3 Stocks Built to Weather Market Volatility
Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets. 
Via MarketBeat
Topics Economy
The S&P 500 Is in Correction Territory: 4 Surefire Stocks to Buy Right Now
Amazing deals abound within Wall Street's benchmark index. 
Via The Motley Fool
Topics Stocks
Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
Large-cap stocks worst performers last week: TER, TTD, COIN, SAIL, GMAB, IBKR, DAL, ADBE, EXPE, HOOD, UAL, AAPL. Are they in your portfolio? 
Via Benzinga
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
What 14 Analyst Ratings Have To Say About Johnson & Johnson
Via Benzinga
What the Options Market Tells Us About Johnson & Johnson
Via Benzinga
Allegations of Inflated Prescription Drug Costs Spark Employee Lawsuit Against JPMorgan
A lawsuit has been lodged against JPMorgan Chase by its employees, who claim that the company's prescription drug plan consented to pay exorbitant prices for medications. 
Via Benzinga
Topics Lawsuit
Kroger CEO Shake-Up
Via The Motley Fool
Cool, Calm, and Collected: 2 Dividend ETFs to Buy During the S&P 500 Sell-Off
Via The Motley Fool
Topics ETFs Stocks
Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025
Via The Motley Fool
Topics ETFs Stocks
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You?
Vanguard has some excellent dividend ETFs, but they are right for different investors. 
Via The Motley Fool
Topics ETFs
Are High-Yield Dividend Stocks Best For Income-Focused Investors?
When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield. But are high-yield stocks always the best route for income-focused investors?... 
Via Talk Markets
Topics Stocks / Equities
How Exxon Mobil, Johnson & Johnson, And Cogent Communications Can Put Cash In Your Pocket
Via Benzinga
2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger
Via The Motley Fool
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints. 
Via Benzinga
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
The company is looking to take on Bristol Myers Squibb's Sotyktu in plaque psoriasis treatment. 
Via Investor's Business Daily
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
3 Dividend Kings Shaking Off Market Woes
The market has thrown a tantrum over recent weeks following tariff news and other economic data pointing to a slowing consumer base. While it’s certainly been a turbulent period, several stocks have... 
Via Talk Markets
Topics Stocks / Equities World Trade
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion 
Via Benzinga
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025. 
Via Benzinga
Broaden Your ETF Exposure With These 3 Overlooked Funds
These ETFs have outperformed the market so far in 2025 but have lower asset bases than some of the most popular funds among investors. 
Via MarketBeat
Topics ETFs Economy Government
2 Dow Stocks to Buy Hand Over Fist in March and 1 to Avoid
Two of the Dow Jones Industrial Average's 30 components make for no-brainer buys, while another brand-name member continues to suffer from self-inflicted wounds. 
Via The Motley Fool
Topics Stocks
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations
From Johnson & Johnson
Via Business Wire
Tech Sector Hammered As Trump's Tariff Plans Spark Market Selloff: Nvidia, ARM, Super Micro Lead Tech Bloodbath
U.S. markets suffered a steep selloff Monday as President Donald Trump announced sweeping new tariffs, extending last week's losses and driving declines across all major sectors. 
Via Benzinga
Topics Government World Trade
Warren Buffett's State of the Market
Berkshire's cash hoard is approaching "Dr. Evil" levels. 
Via The Motley Fool
These Vanguard ETFs Show Where the Smart Money Is Moving Now
Via The Motley Fool
Topics ETFs
3 Top High-Yield Dividend Stocks I Plan to Buy in March for More Passive Income
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.